GPR84 Antagonist IPF Treatment Avoiding Nintedanib
Solution Overview
Problem
Current treatments for idiopathic pulmonary fibrosis (IPF) often result in increased serious adverse events when combined with nintedanib, necessitating the avoidance or discontinuation of concomitant use to mitigate adverse effects.
Innovation Solution
Administering Compound 1, a GPR84 antagonist, while avoiding or discontinuing the use of nintedanib to treat IPF, thereby minimizing adverse events and optimizing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combined therapy with nintedanib and Compound 1 is used to treat IPF, then therapeutic efficacy is enhanced, but adverse events increase
Solution Approach 1:
The patent extracts nintedanib from the combination therapy regimen, identifying it as the specific agent that causes adverse events when combined with Compound 1. By removing nintedanib from the treatment protocol and replacing it with alternative therapies that do not share its hepatotoxic side effect profile, the patent maintains therapeutic efficacy while eliminating the harmful interaction.
Solution Approach 2:
The patent introduces an intermediary assessment process involving liver function monitoring and treatment selection guidance. This intermediary system evaluates patient responses and guides clinicians to choose appropriate combination therapies that avoid the harmful nintedanib-Compound 1 interaction, thereby maintaining efficacy while reducing adverse events.
2Object-affected harmful factors
If nintedanib is discontinued to reduce adverse events, then safety profile improves, but treatment options are limited
Solution Approach 1:
The patent establishes universal treatment guidelines that can be applied across multiple IPF treatment scenarios. By identifying the specific interaction between nintedanib and Compound 1, the patent creates a versatile framework that guides clinicians in selecting from multiple alternative treatment combinations, ensuring both safety and treatment versatility across different patient populations.
Solution Approach 2:
The patent changes the treatment parameter by substituting nintedanib with alternative antifibrotic agents that have different side effect profiles. This parameter change maintains the therapeutic goal of treating IPF while altering the drug composition to avoid harmful interactions with Compound 1, thereby preserving both safety and treatment options.
Data Source
AI summary
The present invention relates to improved methods for the use of a compound according to formula I in the treatment of fibrosis, in particular idiopathic pulmonary fibrosis (IPF), by contraindicating combined therapy with specific IPF therapeutic compounds, where the combined therapy results in a poorer adverse event profile.